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Although a number of secreted factors have been dem-
onstrated to be bone regulators, none of these are
unique to bone. Using a viral-based signal-trap strategy
we have identified a novel gene we have termed “osteo-
crin.” A 1280-bp mRNA encodes osteocrin producing a
mature protein of 103 amino acids with a molecular
mass of 11.4 kDa. Osteocrin shows no homology with any
known gene except for two conserved sequence motifs
reminiscent of dibasic cleavage sites found in peptide
hormone precursors. Immunofluorescence and Western
blot analysis confirmed the secretory nature of osteo-
crin. Two protein species were identified in the medium
of cells overexpressing osteocrin, a full-length 11.4 kDa
species and a processed 5 kDa species. Mutation of the
76KKKR79 dibasic cleavage site abolished the appear-
ance of this smaller osteocrin fragment. By in situ hy-
bridization in mouse embryos, osteocrin was expressed
specifically in Cbfa-1-positive, osteocalcin-negative os-
teoblasts. Immunohistochemistry on adult mouse bone
showed osteocrin localization in osteoblasts and young
osteocytes. By Northern blot analysis, osteocrin expres-
sion was only detected in bone, expression peaking just
after birth and decreasing markedly with age. In pri-
mary osteoblastic cell cultures osteocrin expression co-
incided with matrix formation then decreased in very
mature cultures. Treatment of cultures with 1,25-dihy-
droxyvitamin D3 resulted in a rapid dose-dependent
down-regulation of osteocrin expression, suggesting di-
rect regulation. Chronic treatment of primary cultures
with osteocrin-conditioned media inhibited mineraliza-
tion and reduced osteocalcin and alkaline phosphatase
expression. These results suggest that osteocrin repre-
sents a novel, unique vitamin D-regulated bone-specific
protein that appears to act as a soluble osteoblast
regulator.
Bone is a dynamic tissue that is continually being modeled
and remodeled through the coordinated actions of the bone
forming osteoblasts and bone resorbing osteoclasts. Such re-
modeling is necessary to respond to the continually changing
mechanical and regulatory demands placed upon the skeleton
(1–4). The balance of the activity of the osteoblasts and oste-
oclasts is tightly regulated at both the systemic and local levels
through the actions of a number of secreted molecules. System-
ically, calciotropic hormones such as 1,25-dihydroxyvitamin D3
(1,25(OH)2D3)
1 and parathyroid hormone (PTH) can regulate
both bone formation and resorption, acting on both osteoclastic
and osteoblastic cell lineages (5–8), whereas 1,25(OH)2D3 also
acts via the intestine and kidney to regulate systemic calcium
and phosphate availability (9, 10). Other hormones, such as
growth hormone (11), estrogens (12), and thyroid hormone (13)
also influence bone mass. More recently, it has been reported
that the peptide hormone leptin exerts a strong systemic anti-
osteogenic effect when activating the sympathetic nervous sys-
tem through a hypothalamic relay (14, 15).
Remodeling occurs in discrete units, termed basic multicellu-
lar units, consisting of a cone of cutting osteoclasts followed by
osteoblasts laying down a new collagenous matrix (16, 17). Os-
teoblasts also secrete abundant amounts of non-collagenous pro-
teins, which play key roles in the maturation and mineralization
of the bone matrix (18, 19). In addition to building bone, the
osteoblasts are directly and indirectly involved in regulating bone
metabolism. Osteoblasts secrete molecules that regulate oste-
oclastogenesis and/or osteoclast activity, such as receptor activa-
tor of NFB ligand and osteoprotegerin (20) and also release
growth factors into the bone matrix, such as members of the
insulin-like growth factor, transforming growth factor, and fibro-
blast growth factor families (21). These factors are thought to be
stored and released during successive remodeling cycles to con-
trol local bone formation and resorption (21–23). Insulin-like
growth factor-1 and basic fibroblast growth factor, for example,
act in a paracrine fashion stimulating osteoblast proliferation
and activity (24–27).
It should be noted that none of the secreted bone regulatory
proteins described to date are specifically expressed by bone cells.
In fact, currently, only four highly bone-specific genes have been
identified, two key transcription factors (Cbfa-1 (28) and osterix
(29)) and two structural proteins (bone sialoprotein (30) and
osteocalcin (31, 32)). To identify novel potential bone-specific
regulatory molecules, we undertook to screen cDNA libraries
from bone using a viral-based signal trap technology (33). We
report here the identification of a novel gene specifically ex-
pressed in osteoblasts. The protein contains dibasic cleavage sites
conserved in vertebrate homologues and reminiscent of those
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found in hormonal precursors. Functionally, this novel protein
appears able to modulate osteoblastic differentiation.
MATERIALS AND METHODS
Cloning of Full-length Mouse Osteocrin cDNA—We have previously
developed a screening system that allows the rapid identification of
nucleic acids encoding signal peptides from complex libraries of cDNA
fragments (33). A library enriched in 5 fragments of cDNAs derived
from developing calvaria (33) was obtained using a protocol adapted
from the “oligo-capping” method (34).
The original osteocrin fragment retrieved from this screening proto-
col comprised nt 1–430 of the corresponding full-length clone (Fig. 1),
which was subsequently obtained using a modified 3-RACE strategy as
follows. Five g of e15.5 mouse calvaria total RNA was reverse-tran-
scribed with Superscript IITM (Invitrogen) using a dT15 primer-linker.
cDNA was subjected to 25 cycles of PCR with the TitanTM RT-PCR kit
(Roche) using forward primer 25–10G (see Table I for primer sequences)
and reverse primer 18–30V, complementary to the 5 portion of the dT15
primer-linker (underlined). The PCR products were cloned in place of
green fluorescent protein into the pQBI25fc3 cytomegalovirus-based
expression vector (qBiogene, Montreal, Canada) and the coding se-
quence of osteocrin amplified by RT-PCR using TitanTM and primers
25–10G and 24–10G. The cDNA encoding the mutant osteocrin protein
(mut-osteocrin, 128 aa), in which the 76KKKR79 was changed into
76AS77, was constructed by mismatch PCR. Briefly, the wild-type mouse
osteocrin expression vector was used as a template for two separate
amplifications with Vent DNA polymerase (New England Biolabs, Mis-
sissauga, Ontario, Canada) and the following primer pairs 25–10G
(forward) and 24–10Gmut (reverse), and 25–10Gmut (forward) and
24–10G (reverse). Each PCR product generated was digested with
NheI, purified, and rejoined with T4 DNA ligase. All PCR products were
cloned into the pQBI25fc3 vector and verified by dye terminator cycle
sequencing (DTCSTM sequencing kit, Beckman Coulter, Fullerton, CA)
on a Beckman CEQ 2000 automated sequencer.
Cloning of Vertebrate Homologues of Osteocrin—Human and rat os-
teocrin were cloned by standard RT-PCR starting from 50 ng of bone
marrow poly(A) RNA (Clontech Inc, Palo Alto, CA) or 5 g UMR106
osteosarcoma cell total RNA (ATCC, Manassas, VA), respectively. RT-
PCR was performed with TitanTM with a common forward primer
(18–131G) and specific reverse primers (human, 19–9G; rat, 21–9G).
For snake osteocrin, total RNA was extracted from the vertebrae and
surrounding muscles of a 2-month-old (130 g) Burmese python using
TrizolTM (Invitrogen) according to the manufacturer’s protocol. First-
strand cDNA was synthesized using dT15 primer-linker and Superscript
IITM. cDNA was then subjected to 33 cycles of PCR using rTaq DNA
polymerase (NEB) with forward primer 23–4V and reverse primer
23–6V. 3-RACE was then performed as described above with forward
primer 19–14G and reverse primer 18–30G.
Production of Antibodies—A synthetic peptide (120CMDRIGRNRL-
SNSRG133) corresponding to the last 14 residues of human osteocrin
preceded by an extra cysteine, was conjugated to activated keyhole
limpet hemocyanin via sulfhydryl groups. The peptide/carrier complex
was mixed with complete Freund’s adjuvant and injected into rabbits
according to standard protocols (Affinity Bioreagents, Golden, CO).
Cell Culture and Transfections—Primary calvarial osteoblasts were
cultured from 19–20-day-old embryonic rats based on a previously
described protocol (35). Briefly, calvaria were subjected to 5 sequential
20 min digests in 1 mg/ml collagenase (Worthington, Lakewood, NJ)/
0.25% trypsin (Roche)/0.05% EDTA). Cells from digests 2–5 were pooled
and seeded at 10000 cells/cm2 in -minimal essential medium contain-
ing 10% (v/v) fetal calf serum, 100 units/ml penicillin, 100 g/ml strep-
tomycin, 40 mg/ml gentomycin, 20 mM HEPES, 2 mM glutamine, 50
g/ml ascorbic acid (all Invitrogen) with or without 10 mM -glycero-
phosphate (GP) (Sigma) depending on experimental conditions. Media
was changed after 2 days and every 2–3 days thereafter. Cultures were
treated with 1,25(OH)2D3 (Sigma) or ethanol vehicle at various concen-
trations and for differing time periods as noted for each experiment. For
transfections experiments, HEK293 (qBiogen) and UMR106 cells were
cultured in Dulbecco’s modified Eagle’s medium with 10% (v/v) fetal calf
serum, 50 units/ml penicillin, and 50 g/ml streptomycin. Cells were
transiently transfected with 500 ng of plasmid DNA/106 cells using
EffecteneTM (Qiagen, Mississauga, Ontario, Canada) according to the
manufacturer’s instructions. Media was changed after 6 h, and cells
were left for an additional 16 h before washing with phosphate-buffered
FIG. 1. Full-length cDNA, deduced amino acid sequence, and
genomic structure of mouse osteocrin. A, the full-length mouse
cDNA is 1280 bp and contains an open reading frame of 393-bp flanked
by 61 and 811 bp of untranslated sequences at the 5 and 3 ends,
respectively. The ATG start codon, the TGA stop codon and the poly-
adenylation signal and site are in boldface. The mouse gene produces a
protein of 130 residues containing a signal peptide (underlined) with
the two predicted signal peptidase cleavage sites marked by arrow-
heads. The two putative dibasic cleavage sites, KKKR and KKR, are
boxed. B, the osteocrin genomic locus on chromosome 16 is 44 kb
containing 5 exons. The dashed lines denote gaps in the publicly avail-
able mouse genomic sequence. Note the exons are not drawn to scale.
TABLE I
Summary of primers used in PCR amplification under ‘‘Materials and Methods’’
Primer identifier Primer sequence 5–3
dT15 primer-linker GAGATGAATTCCTCGAGCTTTTTTTTTTTTTTT
25–10G AAACGCTCTGACTTCTCACAAGATG
18–30V GAGATGAATTCCTCGAGC
24–10G CCATCAGCCTCTGGAACTGGAGAG
24–10Gmut CTTGCTAGCGGTCTCAAATACGTCATTC
25–10Gmut TTCGCTAGCAGCTTCTCTGGCTTTGGG
18–131G AGATGCTCGACTGGAGAT
19–9G GAATCAATTAGCCTCTGGA
21–9G GGAAAGAACTTCACTGAAGTG
19–14G GCTCCTCAACGAATTGGTG
23–4V (degenerate) ACI(GA)(TC)I(CAT)(GC)IGA(AG)G(CA)GAA(GA)TC(AG)GC
23–6V (degenerate) CT(AG)TCIA(TAG)(GC)GG(AG)(GC)(AT)ICC(AG)AAICC
21–14G AGATGCTGGACTGGAGATTGG
21–15G TTCTACCAATCCGATCCATGG
18–9G GTCATTGAGAGCAATGCC
19–12G CAAGGTCATCCATGACAAC
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saline and accumulation in serum-free Dulbecco’s modified Eagle’s me-
dium for 48 h for analysis of secreted products. For conditioned media
treatment of primary osteoblast cultures, media from osteocrin or mock-
transfected HEK293 cells were diluted 1:6 in normal culture media and
replenished every 2–3 days from day 2 until the termination of the
experiment at day 18. To measure 45Ca uptake, 45CaCl2 (1Ci/ml)(Am-
ersham Biosciences) was added to the medium for the last 48 h of the
experiment. Medium was collected and the cells scraped into 5% (v/v)
trichloroacetic acid. Cell/matrix-associated 45Ca incorporation was cal-
culated as a percentage of the total input in the cellular and medium
fractions.
Immunofluorescence and Western Analysis—For immunofluores-
cence detection, cells grown on coverslips were fixed with 4% (w/v)
paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.2, and perme-
abilized with 0.5% Triton X-100TM in PB for 4 min. Cells were then
blocked with PB supplemented with 5% (w/v) dried milk for 30 min.
Cells were then incubated for 1 h with a mix of 1/100 dilution (v/v) of
goat anti-human osteocrin antisera and a 1/50 dilution (v/v) of mouse
anti-rat Golgi 58K protein antibody (Sigma) in PB. Cells were then
incubated in a mix of goat anti-rabbit coupled to AlexaFluor 594 and
goat anti-mouse AlexaFluor 488 (both Molecular Probes, Eugene, OR)
in PB for 1 h. Cells were washed twice and observed by fluorescence
microscopy. All steps were performed at room temperature.
For Western blotting, protein in the conditioned medium was precip-
itated by adding trichloroacetic acid to a final concentration of 10%
(w/v) and incubated on ice for 1 h. After centrifugation at 12000  g for
20 min at 4 °C, the pellet was washed once with chilled acetone, dried
briefly, and resuspended directly in 2 Laemli loading buffer (Bio-Rad,
Mississauga, Ontario, Canada) and boiled. For cell extracts, cells were
rinsed with phosphate-buffered saline and solubilized in lysis buffer (50
mM Tris-HCL, pH8.0, 150 mM NaCl, 2 mM EDTA, 1% IGEPAL-630TM,
and 1% (v/v) protease inhibitor mixture (Sigma)). Cell debris and insol-
uble material were pelleted by centrifugation at 12000  g for 5 min at
4 °C. The soluble proteins were mixed with 1 volume of 2 Laemli
loading buffer and boiled. Proteins were electrophoresed on a 16.5%
denaturing Tris-Tricine polyacrylamide gel (Bio-Rad) and transferred
onto 0.2 m nitrocellulose (Protran, Schleicher, and Schuell, Keene,
NH) according to standard Western blot protocols. All subsequent in-
cubations were performed at room temperature. The membrane was
incubated in a 1/800 dilution (v/v) of osteocrin-antiserum in Tris-buff-
ered saline, 0.1% Tween 20 with 2.5% (w/v) dried milk followed by goat
anti-rabbit horseradish peroxidase (Sigma) diluted 1/30000 in TBST
with 2.5% (w/v) dried milk and the signal visualized with ECLTM
reagent (Amersham Biosciences).
In Situ Hybridization—In situ hybridization was performed on
mouse embryonic tissue sections from e16.5 to e17.5 as described pre-
viously (36). The mouse cRNA antisense probes used were as follows: an
815-bp cbfa-1 fragment (nt 931–1746 of GenBankTM accession number
AF10284), an 187-bp osteocalcin fragment (nt 1–187 of GenBankTM
accession number U11542), and a 431-bp osteocrin fragment (nt 1–431
of sequence shown in Fig. 1A). Cbfa-1 and osteocalcin were exposed for
21 days and osteocrin for 30 days.
Northern and RT-PCR Analysis—RNA was isolated from whole
bones or osteoblastic cell cultures using TrizolTM with glycogen (5
g/ml) as carrier according to the manufacturer’s instructions. For
RT-PCR, cDNAs were generated with Superscript IITM reverse tran-
scriptase and oligo-dT18 priming, and PCR amplification carried out
with gene-specific primers using rTaq DNA polymerase (New England
FIG. 2. Predicted osteocrin protein structure and secretion. A, predicted amino acid sequences from human, bovine, mouse, rat, chicken,
and snake (partial) cDNAs (see “Materials and Methods”). The two dibasic cleavage sites, 76KKKR79 and 110KKR112, are well conserved (boxed).
Shaded residues represent non-conserved residues from the human sequence. Note that the C-terminal half of the protein is highly conserved. B,
immunofluorescent localization with a human osteocrin-specific antibody demonstrates overexpressed osteocrin is clearly visible in the secretory
apparatus of HEK293A fibroblasts and UMR106 osteosarcoma cells (400) colocalizing with the 58K Golgi protein-specific antibody. C, the
majority of osteocrin is detected in the medium of HEK293 cells by Western blot when transiently transfected (lanes 1 and 2). Residual protein in
the secretory apparatus is detected in the cell lysate (lanes 4 and 5). Two exposures of the Western blot are shown to illustrate the underrepre-
sented smaller processed fragments, with the lower panel representing a longer exposure. A doublet can be seen at the expected full-length size
of 11.4 kDa and smaller processed fragments at 5 kDa (lane 1). Mutation of the KKKR site to AS abolishes processing of the protein leaving only
full-length 11.4 kDa bands (lane 2). Equal proportions of media or cell lysate from cultured cells were loaded. WT, wild type; Mut, mutated.
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Biolabs). Gene-specific primers and conditions were as follows: osteo-
crin, forward 21–14G and reverse 21–15G (annealing temp  52 °C, 28
cycles, product 378-bp); GAPDH, forward 18–9G and reverse 19–12G
(annealing temp  56 °C, 33 cycles, product 398-bp).
Northern blots were generated on nylon membranes (Osmonics,
Westborough, MA) by standard methods (37). Filters were prehybrid-
ized for 4 h and hybridized overnight in Church buffer (38) at 65 °C. The
rat osteocrin cDNA probe corresponded to the full coding sequence (Fig.
1A). For rat osteocalcin, a cDNA corresponding to the full coding se-
quence (GenBankTM accession number M25490) was generated by PCR.
A 681-bp mouse fragment corresponding to GenBankTM accession num-
ber J04806 was cloned for the osteopontin cDNA probe. For alkaline
phosphatase, a 341-bp fragment corresponding to GenBankTM acces-
sion number NM013059 was generated. A mouse GAPDH cDNA probe
corresponding to 21 to 956 bp of GenBankTM accession number
M32599 was generated by PCR. Probes were labeled with [-32P]dCTP
using a standard random priming protocol (37).
Immunohistochemistry—Immunohistochemistry was as described
previously (39). Briefly, decalcified tibial sections were stained with
primary osteocrin antibody or preimmune rabbit serum overnight at
room temperature followed by biotinylated goat anti-rabbit IgG (Sigma)
and stained using the avidin-biotin-peroxidase complex technique.
RESULTS
Identification and Cloning of Osteocrin—We previously re-
ported the application of a novel technology, based on a
signal-trap, to identify cDNAs encoding secreted and mem-
brane-bound proteins (33). Screening of a mouse e15.5 cal-
varial bone library identified a 433-bp fragment encoding a
putative translation product containing a signal peptide de-
riving from a novel unannotated gene. A modified 3-RACE
strategy was used to obtain the full-length cDNA. Sequences
from at least five different clones were aligned to reconstitute
the full-length cDNA sequence shown in Fig. 1A. This mouse
cDNA is 1280-bp containing an open reading frame of 393 bp
flanked by 61 bp and 826 bp of untranslated sequences at the
5 and 3 ends, respectively. A polyadenylation signal is found
14 bp upstream of a poly(A) stretch. The putative initiator
ATG codon is found in an adequate Kozak context (AA-
GATGC). Delineation of the corresponding genomic locus was
enabled by BLAST searches of the mouse genome sequence
(www.ensembl.org). The gene is located at chromosome 16B2
(syntenic to human chromosome region 3q28). Covering 44
kb, the mouse gene locus is unusually large for a 1280 mRNA
derived from only 5 exons (Fig. 1B).
Protein Structure and Secretion of Osteocrin—The novel
mouse cDNA encoded a protein of 130 residues containing a
signal peptide (Fig. 1A, underlined). The SignalP v2.0 server
(40) predicted two possible signal peptidase cleavage sites, at
Ala-25 and Ser-27 (Fig. 1A, arrowheads). Initial mass spectro-
metric analyses on a semi-purified preparation gave a size of
11371 Daltons favoring Ser-27 as the predominant cleavage
site. Such a size also matched exactly the predicted molecular
weight from the sequence suggesting no post-translational
modifications. The mature 11.4-kDa protein has an isoelectric
point of 10.02. Extensive in silico analysis suggested that the
protein presented no strong homology with any known protein
or protein domains. However, two sequence motifs reminiscent
of dibasic cleavage sites found in peptide hormone precursors
were evident: KKKR at position 76–79 and KKR at position
110–112 (Fig. 1A, boxed). Such putative cleavage sites could
create peptides of 48, 30, and 18 aa, respectively. Because of
these features and its bone-specific expression (see “Restricted
Expression of Osteocrin”), we tentatively named this novel
gene osteocrin.
To further investigate the significance of the putative proc-
essing sites in mouse osteocrin, we determined whether the
dibasic sites were conserved in other species. Rat and human
full-length cDNAs and a partial cDNA from snake were cloned
using RT-PCR. In addition, in silico searches (GenBankTM)
FIG. 3. Osteocrin is expressed in osteoblasts. A, in situ localization of osteocrin transcripts in e16.5 mouse ribs. Osteocrin is localized within
a subset of Cbfa-1-positive cells in a subperiosteal layer (per). Active mature osteoblasts are signified by an arrowhead (200). B, expression of
osteocrin in whole e17.5 fore limb. Osteocrin is clearly localized in the osteoblasts on the periphery of the bone (100). C, in e16.5 mouse tibiae,
osteocrin co-localizes with a subset of Cbfa-1-positive cells, exclusive from the more mature osteocalcin-positive cells found on the bone surface and
in the trabecular bone (arrowheads) (400).
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identified a single bovine EST (accession number BF045261)
and two chicken ESTs (accession numbers ChEST861c21 and
ChEST83i24) (41). Overall amino acid homology between dif-
ferent species is high (Fig. 2A), for example human and mouse
sequences are 74% identical (84% similar) and human and
chicken sequences are 59% identical (71% similar). Further,
the dibasic cleavage sites are conserved across species (Fig. 2A)
with the C-terminal half of the protein from the KKKR dibasic
site being the most conserved. For instance, the C-terminal
portion of the human protein (residues 116–133) differs by only
FIG. 4. Osteocrin is a bone-specific gene. A, Northern blot showing bone specificity of mouse osteocrin expression. Osteocrin is only detected
in neonate and adult long bones and calvaria. No message was detected in embryonic (e) or adult (ad) non-bone tissues. Five g total RNA was
loaded. Br, brain; Go, gonads; Te, testes; He, heart; In, intestine; Ki, kidney; Li, liver; Lu, lung; Sp, spleen. B, osteocrin in detected by Northern
blot in rat spleen. The transcript size of adult rat spleen osteocrin is smaller than that for adult rat calvaria. Fifteen g of total RNA was loaded.
The position of the 18 S ribosomal RNA band is marked. C, osteocrin expression was detected in embryonic calvariae and UMR106 cells by RT-PCR.
No expression was detected in MG-63, SaoS-2, undifferentiated (), or differentiated () MC3T3.E1 cells. D, Northern blot showing osteocrin
expression in femora and calvariae in embryonic (e21), newborn (p4), growing (1 month, 1m), adult (3 month, 3m), and aged (8-month, 8m) rats.
In femora, osteocrin expression was highest in newborn rats decreasing significantly in aged rats. Osteocrin expression peaks at 1-month in
calvaria with a less marked decrease in older rats. Twenty-five g of total RNA was loaded. ALP, alkaline phosphatase. For Figs. 4, A–D, GAPDH
represents a loading control. E, immunohistochemistry with an osteocrin-specific antibody showing localization of osteocrin protein to active
osteoblasts (Ob) in adult mouse tibia. The protein is absent from the mature osteocytes (Oc). No staining is visible in the sections stained with
pre-immune serum (400).
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3 amino acids from that of the snake protein (C-terminal 90%
similarity, full-length similarity of 79%).
Functionality of the predicted signal peptide in osteocrin was
confirmed by immunofluorescence in HEK293 human fibro-
blasts and UMR106 rat osteosarcoma cells transfected with a
vector expressing osteocrin. Labeling was clearly localized in
the secretory apparatus of transfected cells, confirmed by colo-
calization with the Golgi apparatus-specific Golgi 58 kDa pro-
tein (Fig. 2B). Western blot analysis of transfected HEK293
cells demonstrated that osteocrin was constitutively secreted
and accumulated in the culture medium of transfected cells
(Fig. 2C, lane 1). Similar accumulation (data not shown) and
localization (Fig. 2B) was seen in UMR106 osteoblasts trans-
fected with the same vector. Some osteocrin was also detected
in the cellular extract, most likely residual from the secretory
apparatus (Fig. 2C, lane 4). No signal was detected in the
mock-transfected HEK293 cells (Fig. 2C, lane 3). Three bands
were visible in the media. Two closely separated bands can be
seen at 11.4 kDa, which might arise from alternate or incom-
plete processing of the signal peptide, as described above. The
third band, at 5 kDa, could represent the 51-aa fragment
generated by processing at the 76KKKR79 dibasic cleavage site
(Fig. 2C, lane 1). To test this hypothesis, we substituted an
alanine and a serine for the 76KKKR79 site. Due to the replace-
ment of 4 charged residues (KKKR) with two uncharged resi-
dues (AS) in the mutated osteocrin, the mutated molecule
migrated at a slightly lower position than the native molecule
(Fig. 2C, lanes 1 versus 2 and 4 versus 5). Interestingly, the
band at 5 kDa was no longer detected in the medium from
cells transfected with the mutated osteocrin cDNA (Fig. 2C,
lane 2), suggesting this dibasic cleavage site is functional.
Difficulties of visualization of small protein fragments may
result in this band being underrepresented. However, longer
exposure demonstrated the smaller band could still not be
detected in the mutant osteocrin-transfected cells (Fig. 2C, lane
2, lower panel).
Restricted Expression of Osteocrin—In situ hybridization us-
ing a probe corresponding to the coding sequence of mouse
osteocrin revealed a very defined and restricted expression
pattern in embryonic mice. Expression first appears at e13.5 in
the bone rudiments (data not shown). Osteocrin expression
highlighted the periosteum in a subset of Cbfa-1-positive cells
of the developing e16.5 ribs (Fig. 3A) and the e17.5 fore limb
(Fig. 3B). Closer examination of e16.5 tibiae demonstrated that
osteocrin was expressed in periosteal osteoblasts that are Cbfa-
1-positive but osteocalcin-negative (Fig. 3C).
By Northern blot analysis, osteocrin message could not be
detected in tissues other than bone (Fig. 4A) except for a
smaller sized transcript detected in rat spleen (Fig. 4B). Clon-
ing and sequencing of this isoform suggested it is transcribed
from an alternate promoter upstream of the third exon of the
gene. The significance of this rat isoform is unclear because it
does not contain an open reading frame. Furthermore, no such
transcript was detected in mouse spleen.
By high cycle number RT-PCR (40 cycles), we could detect
expression of osteocrin in muscle, kidney, testes, and heart,
albeit at very low levels (data not shown). Osteocrin expression
was detected in the UMR106 rat osteosarcoma cell line but not
in undifferentiated and mineralizing mouse MC3T3 osteoblasts
or human MG-63 and SaOS-2 osteosarcoma cell lines (Fig. 4C).
In bone, expression of osteocrin was highest in embryos and
neonates, peaking at 4 days of age in both calvaria and long
bones and decreasing steadily with age to very low levels in 8-
month-old long bones (Fig. 4D). The age-related decrease was
FIG. 5. Osteocrin is expressed during osteoblast matrix production and maturation. Northern blot of a time course of calvarial primary
osteoblast differentiation at confluence and 5 and 10 days post-confluence in the presence and absence of 10 mM GP (PO4). Osteocrin is expressed
at 5 and 10 days post-confluence but not at confluence. Cultures maintained in 10 mM GP until 10 days post-confluence exhibit a marked
down-regulation in osteocrin expression. Osteocalcin and osteopontin expression are highest at 10 days post-confluence and are increased by GP
treatment. Twenty g of total RNA was loaded. GAPDH represents a loading control. Duplicate samples are shown.
FIG. 6. Osteocrin is down-regulated by 1,25(OH)2D3 treatment.
Effects of 1,25(OH)2D3 treatment on osteocrin expression in 6 day
post-confluent primary calvarial osteoblast cultures. A, Northern blot of
cultures treated with 108 M 1,25(OH)2D3 over a 48 h time course.
Osteocrin expression is down-regulated after 6 h of treatment and
abolished after 48 h of treatment. Osteocalcin expression is up-regu-
lated after 2 h of 1,25(OH)2D3 treatment. Twenty g of total RNA was
loaded. B, dose response of osteocrin expression to 48 h 1,25(OH)2D3
treatment by RT-PCR. Osteocrin was down-regulated by 107 M, 108
M, and 109 M but not 1010 M 1,25(OH)2D3. GAPDH represents a
loading control. Duplicate samples are shown.
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less marked in calvaria by 8 months. Partitioning of long bones
into midshaft (diaphysis and metaphysis) and epiphyseal re-
gions demonstrated predominant expression of osteocrin in the
diaphysis and metaphysis (data not shown). Maximal expres-
sion of osteocrin is reached earlier than that seen for osteocal-
cin, a marker of osteoblast activity but coincided more with
that of tissue-nonspecific alkaline phosphatase. The relative
expression levels of osteocrin were very low, as shown by a
significantly longer exposure time (72 h) compared with osteo-
calcin (3 h).
Immunohistochemical localization using antibodies raised
against the C-terminal region of osteocrin indicated that the
protein was primarily synthesized by cuboidal osteoblasts on
the endosteal surface of adult mouse long bones (Fig. 4E).
Flattened preosteoblasts and newly formed osteocytes were
also labeled, whereas mature entombed osteocytes were not.
Regulation of Osteocrin Expression in Calvarial Cul-
tures—As expected from the in situ data, expression of osteo-
crin was evident in Northern blot analysis of primary calvarial
osteoblastic cells (Fig. 5). Expression was first observed in
conjunction with matrix formation between confluence and 5
days post-confluence. This point coincided with the onset of
osteocalcin expression and significant up-regulation of os-
teopontin expression. Osteocrin expression was maintained
through the mineralization phase 10 days post-confluence. In-
terestingly, primary osteoblasts cultured with 10 mM GP for
10 days post-confluence exhibited decreased osteocrin expres-
sion, corresponding with the development of a very differenti-
ated phenotype in these cultures. This down-regulation was,
however, not observed for osteocalcin and osteopontin.
The bone-specific nature of the expression of this novel gene
led us to investigate whether it was regulated by any of the
major calciotropic hormones. Both PTH (108 M) and dexa-
methasone (108 M), a synthetic glucocorticoid, had no effect on
osteocrin expression (data not shown). However treatment of
mature cultures of rat primary osteoblasts with 108 M
1,25(OH)2D3 in the absence of GP showed significant reduc-
tion after only 6 h and completely abolition of osteocrin expres-
sion by 48 h (Fig. 6A). Osteocalcin expression was up-regulated
in a similar time frame after 2 h of 1,25(OH)2D3 treatment (Fig.
6A). Dose response showed that expression was repressed by
107 M and 108 M, to a lesser extent by 109 M but not by 1010
M 1,25(OH)2D3 (Fig. 6B). Such time and dose response charac-
teristics suggest direct regulation of osteocrin by 1,25(OH)2D3.
Osteocrin Blunts Terminal Differentiation of Osteoblasts—
The biological activity of osteocrin products was assessed using
conditioned medium from HEK293 fibroblasts transiently
transfected with an expression vector for osteocrin. Primary
osteoblasts were chronically treated with conditioned media
from osteocrin- or empty vector-transfected cells from day 2 in
culture (pre-confluence) until 10 days post-confluence (the min-
eralization phase). We estimated by direct enzyme-linked im-
munosorbent assay that the concentration of osteocrin products
in conditioned media was in the order of 5 g/ml. Treatment
with osteocrin-containing medium resulted in a 60% decrease
in mineralization as measured by 45Ca uptake relative to
empty vector (3.67% versus 1.61%, p  0.01) (Fig. 7A). Further,
osteocalcin expression was almost completely abolished and
alkaline phosphatase expression markedly reduced by treat-
ment with osteocrin-containing medium (Fig. 7B).
DISCUSSION
This report describes a novel secreted bone-specific protein
that we have termed osteocrin. A cleavable signal peptide is
found at the N terminus of the 130 aa mouse protein. Accord-
ingly, the bulk of osteocrin is secreted in the culture medium by
transiently transfected fibroblasts and osteoblast-like cells. Os-
teocrin presents no homology to any known protein or protein
domain. However, there are two dibasic cleavage sites for mem-
bers of the mammalian subtilisin/Kex20-like endoprotease
family (42, 43). These putative processing sites are conserved
in the osteocrin molecule from terrestrial vertebrates, from
snake to human. Further, homology across species is particu-
larly high in the C-terminal half of the molecule, between the
putative cleavage sites. The presence and evolutionary conser-
vation of the dibasic sites found in osteocrin are suggestive of
processing similar to that seen for hormones such as proopi-
omelanocortin (44), PTH (45), and parathyroid hormone-re-
lated protein (46, 47). In addition, it is noteworthy that all the
species of cloned osteocrin have a glycine residue at the C
terminus. This raises the possibility that osteocrin products
may be amidated, another feature found in many peptide hor-
mones (48, 49). We have shown that processing of osteocrin
occurs in transfected fibroblasts producing an immunoreactive
fragment of 5 kDa. Importantly, this fragment is not pro-
duced when the dibasic site at position 76–79 is mutated,
indicating that it arises from cleavage at this site. Processing of
the overexpressed osteocrin is not complete with significant
amounts of the 11.4-kDa signal peptide-cleaved form of the
protein being released. However, previous studies (50, 51) have
indicated that prohormone overexpression can lead to a satu-
ration of processing.
Osteocrin appears to be expressed in a subset of osteoblasts.
It is expressed in bone from an early developmental stage
FIG. 7. Osteocrin regulates the osteoblast phenotype. Primary calvarial osteoblastic cultures were treated with conditioned media from
osteocrin or empty vector (control) transfected HEK293A cells from day 2 to 10 days post-confluence. A, 45Ca uptake was reduced 60% by osteocrin
conditioned-media. Data is expressed as the mean  S.E. of the % 45Ca incorporated into the cultures. *, p  0.01. B, Northern blot demonstrating
total repression of osteocalcin and a marked reduction in alkaline phosphatase expression in osteocrin treated cultures. Fifteen g of total RNA
was loaded. GAPDH represents a loading control. Duplicate samples are shown.
Novel Bone-specific Secreted Protein 50569
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(e13.5) being found in the Cbfa-1-positive osteoblast population
though it does not co-express with the mature osteoblastic
marker osteocalcin. In adult bone, the protein is found in active
osteoblasts and early osteocytes but not in terminal osteocytes,
again suggesting expression in a subset of cells. Further, in
adult bone, osteocrin appears to be localized to the endosteal
surface, which is purported to be more active (52, 53).
Temporally, peak expression of osteocrin in bone was just
after birth with expression levels decreasing in aged bones.
Such a reduction in expression with age is consistent with a
role in osteoblast formation and/or activity, which is known to
decrease with age (54–57). Age-related decreases in expression
have been described for osteocalcin (56, 58) and another mature
osteoblast marker, phosphate-regulating gene with homologies
to endopeptidases on the X chromosome (PHEX), an endopep-
tidase involved in phosphate regulation (59). Consistent with
its earlier expression during osteoblast differentiation how-
ever, osteocrin levels diminish before those of osteocalcin. The
age-related decrease in osteocrin expression is less marked in
calvaria than long bones, possibly reflecting the fact that cal-
varial bones play a more protective role and as such, respond
differently to physiological and regulatory demands, such as
PGE2 or bed-rest (60–63) than load-bearing long bones. Differ-
ences in gene expression have been previously described in
osteoblasts and osteoclasts from long bones and calvaria (64).2
In vitro, osteoblasts display a very defined maturational phe-
notype (65). After an initial proliferative phase, the osteoblasts
reach confluence and start to lay down a collagenous matrix. This
is followed by the maturation of the matrix as a number of
non-collagenous proteins are secreted into the matrix. Finally the
matrix is mineralized forming a bone like layer. In this model,
osteocrin expression coincides with the production and matura-
tion of the bone matrix and is maintained at a constant level
during this maturation period, suggesting a role in the active
osteoblast. In contrast, other markers of osteoblast differentia-
tion, such as osteocalcin, display a more linear expression pat-
tern, with expression continuing to increase during the mineral-
ization phase of the osteoblasts (65, 66).
Expression of osteocrin is rapidly and dose-responsively
down-regulated by 1,25(OH)2D3. Changes in RNA levels occur
within 6 h of treatment, similar to other directly up-regulated
(osteocalcin (67) and osteopontin (68)) and down-regulated
(bone sialoprotein (69) and Cbfa-1 (70)) vitamin D responsive
genes. All these genes are regulated by 1,25(OH)2D3 through
well defined vitamin D response elements (71, 72). Preliminary
in silico analysis of the 5 upstream regions of the human and
mouse osteocrin genes revealed putative VDREs 4.6 and 5.6
kb upstream of Exon 1, respectively. Whether these motifs are
functional or modulate the 1,25(OH)2D3 repression of osteocrin
has yet to be confirmed.
In very mature primary osteoblastic cultures, terminal dif-
ferentiation occurs (in this case induced by long-term culture in
the presence of 10 mM GP), resulting in apoptosis or the
assumption of a more osteocytic phenotype (73–75). Such ter-
minal differentiation results in a significant reduction in osteo-
crin expression, whereas reductions in expression of osteoblast
markers such as osteocalcin or alkaline phosphatase (both ex-
pressed in osteocytes) do not occur. Thus, there appears to be a
defined window of osteocrin expression reflecting osteoblast
activity. Taken together with vitamin D regulation, these re-
sults suggest a role for osteocrin in the modulation of the
mature osteoblast phenotype. This hypothesis is supported by
the marked inhibition of mature osteoblastic functions ob-
served upon treatment of primary osteoblasts with osteocrin-
conditioned media. Mineralization was reduced together with
expression of the mineralization-associated genes, alkaline
phosphatase and osteocalcin. The concentration of osteocrin in
the conditioned medium may represent supraphysiologic lev-
els, but it has been suggested that local concentrations of other
bioactive molecules such as insulin-like growth factor-1 and
fibroblast growth factor 2 could be similarly high in the bone
matrix (76). Osteocrin may therefore act directly on osteoblasts
via autocrine or paracrine pathways.
In summary, osteocrin is a novel bone-active molecule that
has no homology to any known protein family. The bone-spe-
cific expression pattern, direct-regulation by vitamin D and
ability to modulate in vitro osteoblast function suggests that
osteocrin represents a novel soluble regulator of bone metabo-
lism. Further elucidation of the function and activity of osteo-
crin may provide new avenues for bone therapeutic approaches.
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